Bio-Path Holdings, Inc. (BPTH)

Market Cap	1.29M +26.8%
Revenue (ttm)	n/a
Net Income	-4.13M
EPS	-0.30
Shares Out	50.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Open	0.0150
Previous Close	0.0300
Day's Range	0.0150 - 0.0300
52-Week Range	0.0102 - 0.1284
Beta	-0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 20, 2026

About Bio-Path Holdings

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: BPTH

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error